Purple Biotech (PPBT) Return on Capital Employed (2015 - 2026)
Purple Biotech (PPBT) reported Return on Capital Employed of 248.21% for Q1 2026, up 22433.0% year-over-year from N/an in Q1 2025, and up 85.91% quarter-over-quarter from 133.51% in Q4 2025.
Purple Biotech (PPBT) Return on Capital Employed (2015 - 2026) Analysis & Trends
Purple Biotech (PPBT) has 12 years of Return on Capital Employed data on file, last reported at 248.21% in Q1 2026.
- Return on Capital Employed for Q1 2026 came in at 248.21%, up 22433.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 248.21% (up 22433.0% YoY), and the FY2025 annual result was 140.44%, up 11044.0% from the prior year.
- Return on Capital Employed improved to 248.21% in Q1 2026 per PPBT's latest filing, from 133.51% in the prior quarter.
- Over five years, Return on Capital Employed peaked at 248.21% in Q1 2026 and troughed at 16.39% in Q3 2025.
- A 5-year average of 59.54% and a median of 45.64% in 2022 frame the typical range for Return on Capital Employed.
- The sharpest annual moves came in 2025 and 2026: Return on Capital Employed slumped 4565 bps in 2025, then surged 22433 bps in 2026.
- A 5-year view of Return on Capital Employed shows it stood at 45.64% in 2022, then surged by 39 bps to 63.48% in 2023, then sank by 46 bps to 34.51% in 2024, then jumped by 287 bps to 133.51% in 2025, then soared by 86 bps to 248.21% in 2026.
- Business Quant data shows PPBT's Return on Capital Employed at 248.21% in Q1 2026, 133.51% in Q4 2025, and 16.39% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 814,307.08 Bn | 814,307.05 Bn | - | - |
| 2 | Belite Bio | 55,320.00 Bn | 55,320.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,149.72 Bn | 17,149.72 Bn | - | 450.31% |
| 4 | Legend Biotech | 3,590.00 Bn | 3,589.71 Bn | 242.10 Mn | 51.73% |
| 5 | Akari Therapeutics | 1,650.72 Bn | 1,650.72 Bn | - | -107.40% |
| 6 | Evaxion A | 1,522.09 Bn | 1,522.07 Bn | - | - |
| 7 | Psyence Biomedical | 229.39 Bn | 229.38 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 113.09 Bn | 105.85 Bn | 2.59 Bn | 21.10% |
| 9 | Abivax | 90.15 Bn | 90.15 Bn | - | -50.43% |
| 10 | Purple Biotech | 242.86 Mn | 236.43 Mn | - | 248.21% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 248.21% |
| Dec 31, 2025 | 133.51% |
| Sep 30, 2025 | 16.39% |
| Jun 30, 2025 | 17.66% |
| Mar 31, 2025 | 23.88% |
| Dec 31, 2024 | 34.51% |
| Sep 30, 2024 | 54.19% |
| Jun 30, 2024 | 63.30% |
| Mar 31, 2024 | 64.38% |
| Dec 31, 2023 | 63.48% |
| Sep 30, 2023 | 55.93% |
| Jun 30, 2023 | 48.04% |
| Mar 31, 2023 | 42.28% |
| Dec 31, 2022 | 45.64% |
| Sep 30, 2022 | 38.26% |
| Jun 30, 2022 | 31.90% |
| Mar 31, 2022 | 30.68% |
| Dec 31, 2021 | 26.50% |
| Sep 30, 2021 | 29.97% |
| Jun 30, 2021 | 29.08% |